Macrogenics (MGNX) Income from Non-Controlling Interests (2015 - 2026)
Macrogenics' (MGNX) quarterly Income from Non-Controlling Interests came in at -$59000.0 in Q1 2026, down 1080.0% year-on-year from $6020.4 in Q1 2025, and down 318.52% on a QoQ basis from $27000.0 in Q4 2025.
Macrogenics (MGNX) Income from Non-Controlling Interests (2015 - 2026) Analysis & Trends
Macrogenics (MGNX) has 12 years of Income from Non-Controlling Interests data on file, last reported at -$59000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 1080.0% year-over-year to -$59000.0 in Q1 2026; TTM through Mar 2026 was -$26000.0, a 176.47% decrease from a year earlier, with the FY2025 full-year figure at $28000.0, up 180.0% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$59000.0, down from $27000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for MGNX reached as high as $213000.0 in Q3 2022 and fell as low as -$222000.0 in Q1 2022.
- Historically, Income from Non-Controlling Interests has averaged $2058.8 across 5 years, with a median of $11000.0 in 2024.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 5425.0% in 2022 and fell as far as 1333.33% in 2022.
- Year by year, Income from Non-Controlling Interests stood at $108000.0 in 2022, then tumbled by 73.15% to $29000.0 in 2023, then slumped by 134.48% to -$10000.0 in 2024, then soared by 370.0% to $27000.0 in 2025, then sank by 318.52% to -$59000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$59000.0 in Q1 2026, $27000.0 in Q4 2025, and $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | -59,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | 29,000.00 |
| Sep 30, 2023 | 38,000.00 |
| Jun 30, 2023 | -80,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | 108,000.00 |
| Sep 30, 2022 | 213,000.00 |
| Jun 30, 2022 | -43,000.00 |
| Mar 31, 2022 | -222,000.00 |
| Dec 31, 2021 | -58,000.00 |
| Sep 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -10,000.00 |